A carregar...
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
OBJECTIVE: To assess if the percentage of CD3(+)CD4(+)CD62L(+) cells in cryopreserved peripheral blood mononuclear cells (PBMCs) (here termed %CD62L) can predict risk of developing progressive multifocal leukoencephalopathy (PML) and better inform the physician for benefit–risk assessment of nataliz...
Na minha lista:
| Publicado no: | Neurology |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4776091/ https://ncbi.nlm.nih.gov/pubmed/26718566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000002314 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|